The condition-specific protocol organization (GI, neuro, immune, athletic) makes it easy for patients to find relevant options
Researchers investigate Big picture view: In the study, researchers at the University of Virginia specifically investigated small-molecule GLP-1 receptor agonists, such as the Food and Drug Administration (FDA)-approved orforglipron, which can be taken orally and are cheaper to produce than their injectable counterparts
Wegovy slashes heart disease risk even before people shed weight Within six months, the drug reduced the risk of cardiovascular death by 50% and cut the risk of needing urgent treatment due to heart failure
They are easy to incorporate into any lifestyle for energy, endurance, and recovery
In: Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors